MONTVALE, N.J., Feb. 24 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced that it has entered into agreements with the current holders of its Series...
MONTVALE, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced that, following a review of its clinical development portfolio and its...
MONTVALE, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has completed enrollment of its BENEFICIAL study, a Phase 2 double-blind...
Company Expects Its Common Stock to Remain Listed While it Engages in Compliance Process MONTVALE, N.J., Dec. 24 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI...
Synvista Therapeutics Technology Provided CML Biomarker Data for Studies MONTVALE, N.J., Dec. 16 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced...
MONTVALE, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has dosed the first patient in a 30-patient Phase 2 clinical trial of its proprietary...
MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (AMEX:SYI) today announced that it has submitted, and that the FDA has received its application for 510(k) clearance...
New Data Presented at the Meeting Demonstrate Vitamin E May Help Prevent Cardiovascular Events in Hp2-2 Diabetes MONTVALE, N.J., Nov. 11 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc...
- Presentation to be Webcast - MONTVALE, N.J. , Nov. 10 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (AMEX:SYI) announced today that Noah Berkowitz, M.D., Ph.D., President and Chief...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관